We also explored if sub-optimal concentrations of romidepsin could be used in a combination treatment strategy, to either sensitize chondrosarcoma to non-epigenetic therapies or to reduce HDAC inhibitor toxicity. The gene discussed is HDAC9; the disease is chondrosarcoma.